Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07091019 · ClinicalTrials.gov registry record
A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- 1,000
- Enrollment target
NCT07091019: Recruiting study, sponsored by Novartis Pharmaceuticals.
NCT07091019 is a clinical trial that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 1,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07091019 is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
Study Summary
This CML disease registry (ASC4REAL-2) aims to gather evidence on the tolerability, safety, effectiveness, and patient-reported outcomes (PRO) in real-world healthcare from patients with Ph+-CML-CP treated with TKIs approved for 1L and 2L, including prospective follow-up for 5 years identifying and describing long-term treatment outcomes.
Primary Outcome
Rate of discontinuation of index Tyrosine kinase inhibitor (TKI) due to Adverse Events (AEs)
Interventions
- OTHER TKIs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-12-17 |
| Est. Completion | 2033-04-20 |
What NCT07091019 shows while recruiting
NCT07091019 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which TKIs is the first listed.
NCT07091019 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07091019 about?
NCT07091019 is a clinical study titled "A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy". This CML disease registry (ASC4REAL-2) aims to gather evidence on the tolerability, safety, effectiveness, and patient-reported outcomes (PRO) in real-world healthcare from patients with Ph+-CML-CP treated with TKIs approved for 1L and 2L, including prospective follow-up for 5 years identifying and ...
What is the current status of trial NCT07091019?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2025-12-17. Estimated completion is 2033-04-20.
What interventions are being tested in trial NCT07091019?
The interventions under investigation include: TKIs (OTHER).
Who is sponsoring clinical trial NCT07091019?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI